---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-001426"
form_type: "8-K"
ticker: "ANIK"
cik: "0000898437"
company_name: "Anika Therapeutics, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T12:32:27.658136+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Anika Q4 revenue up 11% to $39.6M; net loss $4.9M; FY2023 guidance $158-163M

## Summary
- Q4 revenue $39.6M (+11% YoY); OA Pain Mgmt $23.7M (+20%), Joint Preservation $14.3M (+8%).
- Q4 net loss ($4.9M) or ($0.34) per share; adjusted net loss ($3.0M) or ($0.21) per share.
- Full year 2022 revenue $156.2M (+6%); net loss ($14.9M) vs net income $4.1M in 2021.
- FY2023 revenue guidance $158-163M (1-4% growth); OA Pain Mgmt $93.5-96M, Joint Preservation $55.5-58M.
- Hyalofast Phase III trial 199/200 enrolled; Cingal engaging FDA; RevoMotion limited release initiated.

## SEC filing metadata
- accession: 0001171843-23-001426
- form_type: 8-K
- ticker: ANIK
- cik: 0000898437
- company_name: Anika Therapeutics, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/0001171843-23-001426-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/f8k_030623.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-001426
- JSON: https://secwatch.observer/filing/0001171843-23-001426.json
- Plain text: https://secwatch.observer/filing/0001171843-23-001426.txt

## Key facts
- Earnings Releases
  Anika Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: revenue $39.6 million, net income ($4.9) million, EPS ($0.34) per share.
  - Period: the fourth quarter and year ended December 31, 2022
  - Revenue: $39.6 million
  - Net income: ($4.9) million
  - EPS: ($0.34) per share
  - Result: reported results
  source text: Revenue in the fourth quarter of 2022 was $39.6 million, up 11% compared with $35.8 million in the fourth quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/0001171843-23-001426-index.htm
- Earnings Releases
  Anika Therapeutics, Inc. reported fiscal year ended December 31, 2022 results: net income ($14.9) million, EPS ($1.02) per share.
  - Period: fiscal year ended December 31, 2022
  - Net income: ($14.9) million
  - EPS: ($1.02) per share
  - Result: reported results
  source text: Revenue for fiscal 2022 increased 6% to $156.2 million, compared with $147.8 million in 2021
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/0001171843-23-001426-index.htm
- Earnings Releases
  Anika Therapeutics, Inc. reported fiscal year ended December 31, 2022 results: net income ($14.9) million, EPS ($1.02) per share.
  - Period: fiscal year ended December 31, 2022
  - Net income: ($14.9) million
  - EPS: ($1.02) per share
  - Result: reported results
  source text: Net loss was ($14.9) million, or ($1.02) per share, compared to net income of $4.1 million, or $0.28 per diluted share, in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/0001171843-23-001426-index.htm
- Earnings Releases
  Anika Therapeutics, Inc. reported the fourth quarter ended December 31, 2022 results: net income ($4.9) million, EPS ($0.34) per share.
  - Period: the fourth quarter ended December 31, 2022
  - Net income: ($4.9) million
  - EPS: ($0.34) per share
  - Result: reported results
  source text: Net loss was ($4.9) million, or ($0.34) per share, compared to net loss of ($5.8) million, or ($0.40) per share, in the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/898437/000117184323001426/0001171843-23-001426-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.